The gross proceeds from the offering to Evofem, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $100 million.
The offering is expected to close on or about June 5, 2020. In addition, Evofem said that it has granted the underwriters a 30-day option to purchase up to an additional 4.3 million shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Evofem.
Price: 4.0700, Change: -0.59, Percent Change: -12.66
|Lazydays Posts Higher Preliminary Revenue, Recreatio...|
|Sector Update: Tech|
|Midday ETF Update: US Stocks Jump as Q2 Earnings, Va...|
|Sector Update: Health Care|
|Sector Update: Consumer|